Taysha Gene Therapies Past Earnings Performance
Past criteria checks 0/6
Taysha Gene Therapies's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 76.6% per year.
Key information
-7.6%
Earnings growth rate
19.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 76.6% |
| Return on equity | -25.6% |
| Net Margin | -229.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Oct 14More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Jun 27
Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Jun 20Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07Revenue & Expenses Breakdown
How Taysha Gene Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -23 | 29 | 64 |
| 30 Jun 24 | 13 | -114 | 30 | 60 |
| 31 Mar 24 | 14 | -118 | 28 | 65 |
| 31 Dec 23 | 15 | -112 | 30 | 57 |
| 30 Sep 23 | 14 | -214 | 33 | 54 |
| 30 Jun 23 | 10 | -124 | 33 | 60 |
| 31 Mar 23 | 7 | -133 | 35 | 66 |
| 31 Dec 22 | 3 | -166 | 37 | 91 |
| 30 Sep 22 | 0 | -161 | 42 | 116 |
| 30 Jun 22 | 0 | -186 | 44 | 139 |
| 31 Mar 22 | 0 | -193 | 45 | 146 |
| 31 Dec 21 | 0 | -175 | 41 | 132 |
| 30 Sep 21 | 0 | -142 | 36 | 106 |
| 30 Jun 21 | 0 | -106 | 28 | 78 |
| 31 Mar 21 | 0 | -87 | 19 | 50 |
| 31 Dec 20 | 0 | -60 | 11 | 32 |
Quality Earnings: TSHA is currently unprofitable.
Growing Profit Margin: TSHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSHA is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare TSHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: TSHA has a negative Return on Equity (-25.65%), as it is currently unprofitable.